背景:大量研究表明长链非编码RNALINC00662在各种癌症中不规则表达,以及与癌症的发展和进展有关。然而,LINC00662的临床价值仍存在争议。因此,我们通过meta分析和生物信息学分析探讨了LINC00662与癌症预后的相关性.方法:从2022年3月12日开始,我们在WebofScience上搜索相关研究,Embase,PubMed和Cochrane图书馆。我们使用合并风险比(HRs)和比值比(ORs)以及95%置信区间(CIs)来确定人类癌症生存结果和临床病理方面研究的意义。此外,基因表达谱交互分析(GEPIA)数据库用于证实我们的发现.结果:我们对14项研究(共960例癌症患者)进行的荟萃分析显示,LINC00662过表达与癌症患者的总体生存率(HR=1.91,95%CI1.49-2.45,p<0.001)和无复发生存率(HR=2.12,95%CI1.19-3.76,p=0.010)相关。根据癌症类型的亚组分析结果进一步支持LINC00662和OS之间的相关性,随访时间,人力资源可用性,和NOS得分。此外,LINC00662过表达预测晚期肿瘤分期(OR=4.23,95%CI2.50-7.17,p<0.001),肿瘤大小较大(OR=1.49,95%CI1.11-1.99,p=0.008),早期淋巴结转移(OR=2.40,95%CI1.25-4.59,p=0.008),和较早的远处转移(OR=4.78,95%CI2.57-8.88,p<0.001)。然而,年龄差异无统计学意义(OR=1.16,95%CI0.90-1.51,p=0.246),性别(OR=1.10,95%CI0.79-1.53,p=0.578),或分化等级(OR=1.53,95%CI0.71-3.33,p=0.280)。结论:LINC00662表达上调与多发肿瘤患者预后不良及晚期临床病理特征有关。LINC00662可作为肿瘤患者诊断和治疗的生物标志物。
Background: Numerous studies have revealed that the long non-coding RNA
LINC00662 is irregularly expressed in various cancers, as well as is correlated with cancer development and progression. Nevertheless, the clinical value of
LINC00662 remains controversial. Hence, we explored the correlation of
LINC00662 with cancer prognosis through meta-analysis and bioinformatics analysis. Methods: From the beginning through 12 March 2022, we searched for correlational studies on Web of Science, Embase, PubMed and The Cochrane Library. We used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) to determine the significance of studies on survival outcomes and clinicopathological aspects in human cancers. Additionally, the Gene Expression Profiling Interactive Analysis (GEPIA) database was employed to confirm our findings. Results: Our meta-analysis of 14 studies comprising a total of 960 cancer patients revealed that LINC00662 overexpression was correlated with poor overall survival (HR = 1.91, 95% CI 1.49-2.45, p < 0.001) in cancer patients and relapse-free survival (HR = 2.12, 95% CI 1.19-3.76, p = 0.010) in hepatocellular carcinoma patients. The correlation between LINC00662 and OS was further supported by the results of subgroup analyses according to cancer type, follow-up time, HR availability, and NOS score. In addition,
LINC00662 overexpression predicted advanced tumor stage (OR = 4.23, 95% CI 2.50-7.17, p < 0.001), larger tumor size (OR = 1.49, 95% CI 1.11-1.99, p = 0.008), earlier lymph node metastasis (OR = 2.40, 95% CI 1.25-4.59, p = 0.008), and earlier distant metastasis (OR = 4.78, 95% CI 2.57-8.88, p < 0.001). However, there were no statistically significant differences in age (OR = 1.16, 95% CI 0.90-1.51, p = 0.246), gender (OR = 1.10, 95% CI 0.79-1.53, p = 0.578), or differentiation grade (OR = 1.53, 95% CI 0.71-3.33, p = 0.280). Conclusion: LINC00662 expression upregulation is associated with poor prognosis and advanced clinicopathological features in patients with multiple tumors.
LINC00662 may serve as a biomarker for the diagnosis and treatment of patients with tumors.